1 / 7

U.S. Food and Drug Administration

U.S. Food and Drug Administration. Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated. . Public Disclosure and Environmental Assessment.

avel
Download Presentation

U.S. Food and Drug Administration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

  2. Public Disclosure andEnvironmental Assessment

  3. Public Disclosure Questions: (a) should we disclose to the public that we are considering an import tolerance for a new animal drug? If so, (b) when, (c) how, and (d) in how much detail?

  4. Public Disclosure • 21 CFR 514.11 (b) - The existence of an NADA file will not be disclosed by the Food and Drug Administration before an approval has been published in the FEDERAL REGISTER, unless it has previously been publicly disclosed or acknowledged.

  5. Environmental Assessment Question: Will the establishment of import tolerances have a significant effect on the environment?

  6. Environmental Assessment • 21 CFR 25.20 - Actions requiring preparation of an environmental assessment. (m) Approval of NADA’s, abbreviated applications, supplements, and actions on INAD’s, unless excluded under 25.33 (a), (c), (d), (e).

  7. Environmental Assessment • 21 CFR 25.33 - Categorical Exclusions • (a) … if the action does not increase the use of the drug. • (c) … for substances that occur naturally in the environment… • (d) “low environmental exposure” • (e) Action on an INAD.

More Related